In-Depth Examination Of 5 Analyst Recommendations For CARISMA Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for CARISMA Therapeutics (NASDAQ:CARM) over the past quarter, with a majority being bullish. The average 12-month price target has decreased by 13.33% to $7.8. Key analysts from HC Wainwright & Co. and BTIG have maintained or lowered their price targets, reflecting evolving market conditions and company performance.
June 26, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
CARISMA Therapeutics has received mixed analyst ratings, predominantly bullish, but the average 12-month price target has decreased by 13.33% to $7.8. Analysts from HC Wainwright & Co. and BTIG have maintained or lowered their price targets, indicating cautious optimism.
The majority of analysts are bullish on CARISMA Therapeutics, but the decrease in the average price target suggests tempered expectations. The actions of key analysts from HC Wainwright & Co. and BTIG, who have maintained or lowered their price targets, reflect a cautious outlook despite overall positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100